


The Global Virome Project

The Transformative Power of Big Data

Dr. Dennis Carroll
GVP Core Team




0



The Global Virome Project

 **The Challenge:**
We are losing the fight against emerging infectious diseases - despite having spent billions, our understanding of EIDs is inadequate

 **The Concept:**
Equip countries to monitor and characterize the majority of unknown zoonotic viruses in wildlife, and use the data to develop a global knowledge network

 **The Impact:**
Transform virology into a big data science and lay the foundation for the global health community to prevent, detect and respond to threats more efficiently, effectively and proactively

 **The Path Forward:**
A 10-year, coordinated effort across 50 countries, with the first wave of National Virome Projects joining an incubation phase in 2019



1


The challenge



2

The threat of viral outbreaks is growing rapidly...

Largely driven by population growth, wildlife encroachment, and globalization



1. EID: emerging infectious disease; only diseases with zoonotic emergence are included; Reference for graph: Allen et al. (2017) Nature Communications



3

Challenge 

...and there are many high-risk pathogens in wildlife we have not yet discovered



- To date, **111 viral families** have been discovered around the world
- 25 of these families** are likely to be capable of infecting humans
- Across these 25 high-risk families, there are estimated to be **1.7M unknown viruses**
- About **700k of which** likely have the potential to infect humans

We currently know <0.1% of the viruses with zoonotic potential; GVP will get us to 70%

For example, for every known coronavirus, there are currently **thousands of unknown coronaviruses** circulating in wildlife

The same is likely true for other viral families



Carroll et al. (2018) Science

Challenge 

We urgently need to improve our understanding of these threats, and reinvent "what to do about it"



Our knowledge of viral threats barely scratches the surface



Our understanding of the relative risk of these threats is limited



Our capacities to address such threats are inadequate

Despite having spent billions on prevention, detection and response, we have not made much progress



5

The concept



6

The Global Virome Project is a necessary first step

A 10-year effort to collect and characterize the majority of unknown viruses in ~50 countries

Virus identification and genome sequence



Metadata on "viral ecology" - host range, geographic distribution, epidemiology

Documenting >70% of the world's unknown zoonotic threats



7

GVP is a *transformative "down payment"* to lay the foundation for:

- Long-term country capacity
- Sustained, longitudinal surveillance of viral evolution
- Development of an innovative "tool box" for diagnostics, treatments, and prevention

Using learnings from the PREDICT "proof of concept," we can answer several key questions about GVP:

From 2009-2016, USAID invested ~\$140M to strengthen global capacity for viral discovery in 30 countries by:

- **Sampling** wild animals
- **Discovering** novel viruses
- **Training** field and lab staff



1 How many samples do we need to collect?



2 Which geographies and wild life species do we target?




3 What data do we need to collect to be able to gauge spillover risk?

How many samples to we need to collect?

Goal of collecting ~1-2000 samples per species

Collecting ~2000 samples per species yields ~99% of a species' viral diversity



- GVP will collect ~1-2000 samples per species, to be revised based on practicality (e.g., threatened or difficult-to-capture species)
- Some species' curves will saturate even more quickly; curves will be assessed and "early stopping" levels defined to increase efficiency


Anthony et al. (2015) Nature Communications






Which geographies and species do we target?

Mammals and water birds are the principle viral reservoirs



Mammalian Habitat ranges



Waterfowl breeding hotspots



How Many Sites are Needed?

Sites selected to maximize biodiversity, minimize cost; ~70% of mammalian virome found within ~130 sites



- GVP targets **hotspots for mammalian diversity** and **waterbird breeding**; prioritizes sites harboring spillover hosts and distinct species assemblages
- Site selection further refined based on **accessibility, availability of laboratory facilities**
- Sampling at the **regional level** minimizes duplication of sites in adjacent countries, allows **logistical efficiencies** to drive site selection
- Exact site selection to be refined, including with **input from field countries**



Concept 

What data do we need to collect to be able to gauge spillover risk?

40+ data points to be collected

Ecological traits	Viral traits
 Geographic hotspots for emergence	 Host breadth / plasticity
 Host species traits, geographic range, relatedness	 Proportion of known zoonoses in viral family
 Host abundance	 Phylogenetic relatedness to known zoonoses
 Epidemiological / contact interface	 Viral prevalence in host
	 Other virus-specific traits



12

Key questions that can be answered from the data


- How abundant is the virus's host species?
- Where are the hosts distributed geographically?
- Where does the host come into contact with livestock or humans?
- How many hosts species can the virus infect?
- Are other viruses in this viral family known to be zoonotic?
- How close phylogenetically is the virus to other zoonoses?

The impact



13

Three direct "deliverables"



Transforming the basic science of virology into a *field driven by big data* and enabling *sustained longitudinal surveillance* of viral evolution

These deliverables will equip the global health community with the inputs it needs in order to...


...continue to strengthen *key surveillance and lab capacities* even after the GVP concludes

...*identify natural & lab-enhanced pathogens* more rapidly in the event of an outbreak

...improve understanding of individual viruses and viral families for the *development of diagnostics, vaccines & treatments*

...minimize spillover by *targeting surveillance and policies* toward the highest-risk pathogens and geographies

GVP will be an integrating and complementary force



The Path Forward



The go-forward vision: 3 Phases

Path Forward →

1. Incubation Period 2019 - 2021



- Underway in ~2 countries (Thailand and China)
- Science & ops validated, refined as needed
- End users beginning to analyze and act on the data
- Funding secured for first several years, key roles hired

2. Steady State 2022 - 2031



- GVP scales up and launches National Virome Projects across ~50¹ countries
- Local buy-in to continue collecting data and end users investing in its use
- Funding secured for duration

3. Pan-GVP



- Tracking Risk: Longitudinal multisectoral monitoring of viral evolution of "prioritized" viruses (starts during Steady State)
- Expanding the Tool Box End users leveraging new technologies and insights enabled by GVP



Incubation Period:

Path Forward →

Main Objectives

1 Validate the "science" behind GVP



2 Mobilize funding and other resources




3 Build out the GVP organization




Key Points

- *Key scientific elements to validate:* scientific protocols and assumptions; sampling operations and ability to scale efficiently; data platform & analytics
- *Means of validation:* "proof of concept" NVPs in 2 countries; independent SAG of internationally recognized scientists; Working Groups to ensure quality, efficiency, and incorporation of key learnings
- Articulate GVP's value and feasibility to a global network of influential advocates who can introduce GVP into the *political "mainstream"*
- Engage governments and other potential donors to *secure 2-3 years of funding*
- Explain GVP's value to in-country decision makers to *secure next wave of NVPs*
- *Establish formal entity with interim BoD & SAG* to guide GVP strategy, provide financial & scientific oversight, ensure global representation, & seek funding
- *Scale up organization* through phased hiring, starting with an ExD
- Build towards *int'l NFP; finalize data sharing*, licensing protocols and intellectual property rights issues







What GVP IS and What it is NOT




24

GVP NOT

What GVP is NOT!


-  Simply a sequence database
-   A tool to predict the next pandemic
-  An academic exercise
-  At the expense of ongoing viral research
-  A US-based project



GLOBAL VIROME PROJECT

25

GVP 15
=



What GVP Is

-  Global partnership led by partners
-  Promotes equitable access to data and benefits
-  Invests in the systems and capacities for sustainable surveillance
-  Addresses the risks posed by viruses to both animals and humans
-  Transforms the global health culture from being “reactive” to “proactive”


26



GVP 15

GVP ALSO.....


Shares many attributes with the Human Genome Project



-  An **audacious, but doable**, multi-year initiative with clearly defined goals and metrics
-  Completed in **distinct phases** - each generating discrete, useful information
-  Provides a **foundation** to transform the way we engage in global health
-  Potential for a **multitude of applications** above and beyond the immediate outputs
-  Harnesses the **transformational power of Big Data**

27





GVP: A Growing Network



The beginning of the end
... of the pandemic era

